Simulations Plus

Simulations Plus ROE

The Return on Equity (ROE) of Simulations Plus (SLP) as of Sep 27, 2026 is -51.86 %. In the previous year, Return on Equity (ROE) was 5.46 % — a change of -1,050.40% (lower).

ROE

-51.86 %

YoY

-1,050.40%

Last updated:

In 2026, Simulations Plus's return on equity (ROE) was -51.86 %, a -1,050.40% increase from the 5.46 % ROE in the previous year.

The Simulations Plus ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
27.99 USD
Jan 1, 2019
22.78 USD
Jan 1, 2020
5.98 USD
Jan 1, 2021
5.90 USD
Jan 1, 2022
7.00 USD
Jan 1, 2023
5.86 USD
Jan 1, 2024
5.46 USD
Jan 1, 2025
-51.86 USD
The Simulations Plus ROE history
YEARROEYoY
-51.86 %-1,050.40%
5.46 %-6.86%
5.86 %-16.35%
7.00 %+18.69%
5.90 %-1.34%
5.98 %-73.74%
22.78 %-18.62%
27.99 %+24.79%
22.43 %+3.00%
21.78 %+10.68%
19.68 %+0.38%
19.60 %—
Access this data via the Eulerpool API

Simulations Plus Stock analysis

What does Simulations Plus do? Simulations Plus Inc is a company that offers software and services for the pharmaceutical industry. The company was founded in 1996 by Dr. Walt Woltosz and is headquartered in Lancaster, California. Simulations Plus began with the development of GastroPlus, a software that simulates the effects of drugs in the body using mathematical models. This software quickly became an important tool for the pharmaceutical industry to improve the effectiveness and safety of medications. Simulations Plus's business model is based on providing high-quality software and services for the pharmaceutical industry. They offer a wide range of products aimed at improving the effectiveness and safety of drugs by optimizing drug development and design. These products include software for simulating and analyzing the pharmacokinetics and dynamics of medications, a model for detecting and avoiding potential life-threatening liver damage, a cloud-based platform for simplifying the work of scientists and researchers, and services to assist with regulatory affairs and obtaining product approvals. Simulations Plus is known for its high-quality products and excellent customer support, and their various divisions and products contribute to improving the effectiveness and safety of medications, ultimately promoting patient health. The translation of the text is: "Simulations Plus Inc is a company that offers software and services for the pharmaceutical industry. The company was founded in 1996 by Dr. Walt Woltosz and is headquartered in Lancaster, California. Simulations Plus began with the development of GastroPlus, a software that simulates the effects of drugs in the body using mathematical models. This software quickly became an important tool for the pharmaceutical industry to improve the effectiveness and safety of medications. Simulations Plus's business model is based on providing high-quality software and services for the pharmaceutical industry. They offer a wide range of products aimed at improving the effectiveness and safety of drugs by optimizing drug development and design. These products include software for simulating and analyzing the pharmacokinetics and dynamics of medications, a model for detecting and avoiding potential life-threatening liver damage, a cloud-based platform for simplifying the work of scientists and researchers, and services to assist with regulatory affairs and obtaining product approvals. Simulations Plus is known for its high-quality products and excellent customer support, and their various divisions and products contribute to improving the effectiveness and safety of medications, ultimately promoting patient health." Simulations Plus is one of the most popular companies on Eulerpool.

ROE Details

Decoding Simulations Plus's Return on Equity (ROE)

Simulations Plus's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Simulations Plus's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Simulations Plus's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Simulations Plus’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Simulations Plus stock

Return on Equity (ROE) of Simulations Plus is -51.86 % in 2026.

Return on Equity (ROE) of Simulations Plus changed from 5.46 % to -51.86 %, representing a -1,050.40% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Simulations Plus since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Simulations Plus with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

Profitability — Simulations Plus

All Key Metrics — Simulations Plus